Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2020-09-17, Stock:LLY, The news for the past five days is as follows:
2020-09-10: NEWS1: Lilly Announces Webcast to Discuss ESMO 2020 Presentations.NEWS2: Regeneron’s Virus Treatment Has Probably Missed the Bus.NEWS3: Lilly commits Insulin Value Program, featuring $35 copay card, to suite of affordability solutions for people with diabetes.NEWS4: Lilly Oncology to Showcase New Data from Robust Cancer Research Pipeline at ESMO Virtual Congress 2020.
2020-09-11: NEWS1: Lilly to Participate in Cantor Fitzgerald Virtual Global Healthcare Conference.NEWS2: Animal Spirits for Elanco? Pet-Care Company’s Stock Is Well Positioned for Gains..NEWS3: Antibody therapy developer AbCellera hires banks for U.S. IPO -sources.NEWS4: Lilly to Participate in Morgan Stanley Global Healthcare Conference.NEWS5: U.S. Drug Stocks Look Cheap. Here’s Why, According to One Analyst..NEWS6: It’s Likely Too Late for Regeneron’s Virus Treatment.NEWS7: REYVOW™ (lasmiditan) C-V Demonstrated Pain Freedom from Migraine Attacks At 60 Minutes and Up to 48 Hours in New Phase 3 Study.
2020-09-14: NEWS1: Gilead Makes Its Biggest Buy Ever And Gets A 'Flagship' Cancer Drug.NEWS2: Eli Lilly, Incyte Combine Covid Drug With Gilead's, Post Positive Data.NEWS3: Gilead, Pfizer, Eli Lilly CEOs On COVID-19 Treatments, Vaccine Development.NEWS4: COVID SCIENCE-Flu outbreaks may be linked to COVID-19; arthritis drug benefit seen.NEWS5: Balloons at Macy’s Thanksgiving Day Parade Will Be Rigged to Special Vehicles.NEWS6: Eli Lilly's drug cuts COVID-19 recovery time in remdesivir-combo study.NEWS7: Arthritis Drug Helps Covid-19 Patients Recover Faster.NEWS8: Shares of Lilly and Incyte gain after late-stage study finds their arthritis drug can help reduce COVID-19 recovery time.NEWS9: Regeneron's antibody drug added to UK Recovery trial of COVID treatments.NEWS10: Eli Lilly's rheumatoid arthritis drug helps recovery in COVID-19 patients.NEWS11: Baricitinib in Combination with Remdesivir Reduces Time to Recovery in Hospitalized Patients with COVID-19 in NIAID-Sponsored ACTT-2 Trial.NEWS12: Innovent and Lilly Jointly Announce Results of Six Clinical Studies of TYVYT® (sintilimab injection) to be Presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.
2020-09-15: NEWS1: Eli Lilly (LLY) Outpaces Stock Market Gains: What You Should Know.NEWS2: Lilly's Olumiant Meets Primary Endpoint in Coronavirus Study.NEWS3: Lilly Launches Digital Health Open Innovation Challenge to Help Transform Atopic Dermatitis Care.NEWS4: Steve Cohen Finally Buys the Mets. You Can Buy the Braves..NEWS5: US FDA grants Fast Track designation to Jardiance® (empagliflozin) to improve outcomes following a heart attack.
2020-09-16: NEWS1: Lilly announces proof of concept data for neutralizing antibody LY-CoV555 in the COVID-19 outpatient setting.NEWS2: Eli Lilly Posts Positive Data On Covid-19 Treatment In Phase 2 Trials.NEWS3: Lilly's Coronavirus Antibody Treatment Found Effective, Safe In Mild-To-Moderate Patients.NEWS4: Eli Lilly Reports Success With COVID-19 Neutralizing Antibody Treatment.NEWS5: Lilly and Pfizer Are Testing Treatments for Hospitalized Covid Patients.NEWS6: Coronavirus update: Operation Warp Speed readies for vaccine as CDC tries to manage expectations.NEWS7: Dow Jones Rallies 200 Points Ahead Of Fed; Stocks Mixed As Nasdaq Falters.NEWS8: Eli Lilly Says Antibody Lowers Risk of Hospitalization for Mild COVID-19 Patients.NEWS9: Lilly Drug Gets Fast Track to Improve Heart Attack Outcome.NEWS10: Eli Lilly Says Covid-19 Treatment Reduces Hospitalizations.NEWS11: Shares of Lilly gain as it discloses promising interim findings for COVID-19 antibody treatment.NEWS12: Lilly says antibody reduces need for hospitalization for moderate COVID-19 patients.NEWS13: Lilly announces proof of concept data for neutralizing antibody LY-CoV555 in the COVID-19 outpatient setting.NEWS14: The Argus Dividend Growth Portfolio.

Answer: Rise